Board of Directors
Mr. Raj Shah - President, INCTR USA
Mr. Raj Shah, President of INCTR USA, is dedicated to improving global health within the global “communities in need” afflicted with chronic diseases. He is specifically committed to finding individualized health solutions for the chronic disease population. Mr. Shah’s vision is to provide integration of processes for better collaboration and performance at the point of care in order to supply the safest and most cost-effective patient care. With experience in the areas of energy, environment, financial engineering, management consulting, technology development, and infrastructure development projects, Mr. Shah has directed over $1 billion in business through his management roles with Engelhard and Control Data Corporation, both Fortune 100 companies, and now with CTIS, Inc. Mr. Shah has received multiple leadership awards from health institutes and community organizations and serves as a member of the National Advisory Council on Minority Health and Health Disparities. Mr. Shah was invited to the 2010 G20 Health Summit and published a paper on Global Health and Information and Communication Technology.
As a non-profit institute supporter, Mr. Shah has been committed to corporate citizenship by supporting the health care needs of the community. He has also been a member of the governing boards, leadership boards, institutional review boards, trusteeships, board of directors and advisor for over 25 institutes. Mr. Shah has given over 100 lectures, talks and panel memberships at workshops, conferences, and seminars. Mr. Shah has a bachelor’s degree in chemistry/physics from Bombay University, India; a master’s degree in chemistry from University of Detroit, and advanced training from the University of Chicago and Harvard Business School.
Mr. Tim Moynahan
Mr. Tim Moynahan, board member of INCTR USA, is the founding member and first chairman of the Global Virus Network (GVN), a global authority and resource for the identification, investigation, and control of viral diseases posing threats to mankind. He is currently a board member and member of the Executive Committee of GVN.
Mr. Moynahan is also a member of the Post University MBA Advisory Council; the Advisory Board and Executive Committee of the Institute of Human Virology (IHV) of the University of Maryland Biotechnology Institute. Mr. Moynahan is on the board of Let’s Think-Kids Foundation, Inc., a national educational nonprofit organization focused on serving English Language Learners and at-risk minority youth and their families through programs that help improve academic success. He serves as president of the Ireland Chamber of Commerce in the United States and the Connecticut Chapter Ireland Chamber of Commerce-USA (ICCUSA), a non-profit membership organization created to promote the growth of mutually beneficial economic relationships. He also serves as the Attorney Emeritus for the Board of Governance (2012-2014).
Steven Patierno, M.D.
Steven Patierno, M.D., board member of INCTR USA, is the Deputy Director of the Duke Cancer Institute (DCI), a top-ranked National Cancer Institute (NCI), designated Comprehensive Cancer Center dedicated to providing leading-edge, high-technology, compassionate care from diagnosis to treatment to survivorship, advancing multi- and trans-disciplinary cancer research and engaging in authentic prevention and community health programming. With major support from the Amgen Foundation, the DC Cancer Consortium, and the DC Department of Health and the Avon Foundation, Dr. Patierno implemented an innovative Community by Community Cancer Control Campaign to support cancer screening services and eMobile-Health initiatives in Anacostia, the poorest and most medically underserved quadrant of Washington D.C.
Central to the mission of DCI is eliminating cancer health disparities, for which Dr. Patierno has received numerous awards for his leadership in this area. He co-chaired the American Association of Cancer Research (AACR) think tank and multiple national conferences on “The Science of Cancer Health Disparities in Racial and Ethnic Minorities and the Medically Underserved” and has spoken at many national symposiums and conferences, including co-chairing the 2010 Surgeon General’s National Call to Action on Cancer Prevention and Survivorship, as an expert in cancer disparities. He also co-chairs the National Patient Navigation Leadership Consortium.
Mr. Joseph Simone
Mr. Joseph Simone, board member of INCTR USA. Mr. Simone is a business leader, humanitarian, public servant and an internationally acclaimed artist. He co-founded a number of companies and served as an advisor to many of them. Over the last 12 years he performed dual roles in both health related foundation work and entrepreneurial business.
Mr. Simone and his late wife founded the International Spirit of Life Foundation (ISOLF), used at George Washington (GW) University Hospital Cancer Center, Washington D.C. ISOLF is an international organization that recognizes achievements at the highest level in cancer care, treatment, research, and philanthropy. Mr. Simone is an accomplished national platform speaker and an advocate who has given hundreds of motivational speeches and talks nationwide.
Shashank Desai, M.D.
Shashank Desai, M.D., board member of INCTR USA, is the medical director of the Heart Failure / Transplant Program at Inova Heart and Vascular Institute at Inova Fairfax Hospital. He is specialty board certified in heart failure and heart transplant cardiology. He was recruited to Inova Fairfax Hospital in 2006 to guide the 25 year old heart transplant program from his position as an assistant professor at the University of Pennsylvania. His clinical and research expertise encompasses the management of end-stage heart failure with therapies such as heart transplantation and mechanical cardiac support devices. He heads a multidisciplinary team of clinicians to manage complex heart failure at Inova Fairfax Hospital. In the metropolitan Washington, D.C. area, Dr. Desai has developed a clinical network of heart failure / ventricular assist devices (VAD) / heart transplant therapy, increasing access to heart failure services to patients throughout the metropolitan area.
Dr. Desai has been the principal investigator to many multicenter heart failure studies, bringing basic therapies such as angiotensin receptor blockers and biventricular pacemakers to clinical practice. Additionally, he has been a principal investigator to many heart transplant and VAD trials and been involved in numerous investigator initiated studies regarding heart transplantation and VADs. Dr. Desai has spoken nationally and internationally about his experience with end-stage heart failure and VAD therapy.
Ian Magrath, M.D.
Ian Magrath, M.D., board member of INCTR USA, has been the President and Director (Medical and Scientific) of INCTR since 1999, and is Adjunct Professor of Pediatrics at the University of the Uniformed Services in the Health Sciences. He joined the National Cancer Institute (NCI), National Institutes of Health (NIH) in 1974 and became chief of the Lymphoma Biology Section of the Pediatric Oncology Branch. His work at NCI focused on the treatment and molecular pathogenesis of non-Hodgkin lymphomas, particularly Burkitt’s lymphoma, as well as the role of Epstein-Barr virus in the pathogenesis of the latter disease. During the last 25 years, he has had a particular interest in cancer control in developing countries and has been involved in the conduct of cancer control projects, clinical trials, and basic research in many parts of the world, including India, Pakistan, Nepal, China, Mexico, Argentina, Brazil, Turkey, Tanzania, Kenya, Nigeria and Egypt. This led to his present position as President of INCTR in 2000, although he retains a position at NCI.
Dr. Magrath received his qualifications in medicine from the University of London. He holds a higher doctoral degree in Medicine from Imperial College, London University, and is a Fellow of the Royal College of Physicians and the Royal College of Pathologists. He has served on the board of a number of cancer journals and is presently a member of the WHO Technical Committee on Cancer Control and consultant to the WHO Essential Drugs Committee (cytoxics) and serves as INCTR Liaison to the Board of Directors of the International Union Against Cancer (UICC).
